FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, issued today the first formal statement from its Chief Executive Officer Michael A. McManus, Jr. regarding the Company’s High Intensity Focused Ultrasound (“HIFU”) strategy. HIFU is a minimally invasive novel medical technology through which intersecting, precision focused ultrasound waves raise the temperature of the target tissue to 80-90 degrees Celsius in two to three seconds, effectively destroying the targeted cancerous tissues.
